Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 00:50 ET | Source: NVIDIA

NVIDIA Announces NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research

News Summary: NVIDIA announces an open humanoid robot reference design built on the NVIDIA Isaac GR00T platform, combining a Unitree H2 Plus humanoid robot, Sharpa five-fingered hands for dexterous...
June 01, 2026 00:26 ET | Source: NVIDIA

NVIDIA and Microsoft Reinvent Windows PCs for the Age of Personal AI

News Summary: NVIDIA RTX Spark powers the world’s first Windows PCs purpose-built for personal agents, featuring 1 petaflop of AI performance, industry-leading power efficiency, full-stack NVIDIA AI...
May 31, 2026 23:26 ET | Source: Shanghai East International Medical Center (SEIMC)

SEIMC Launches Precision Gallbladder-Preserving Treatment to Safeguard Biliary Health

SHANGHAI, May 31, 2026 (GLOBE NEWSWIRE) -- On March 14, 2026, Shanghai East International Medical Center (SEIMC) achieved a major milestone in global minimally invasive biliary treatment by...
May 31, 2026 19:30 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company...
May 31, 2026 10:00 ET | Source: Precede Biosciences, Inc.

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLCPlasma MET test showed high concordance with tissue...
May 31, 2026 09:00 ET | Source: https://immatics.com/

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck...
May 30, 2026 13:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotideData build upon previously reported COMPETE...
May 30, 2026 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50,...
May 30, 2026 08:00 ET | Source: Molecular Partners

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
May 30, 2026 08:00 ET | Source: https://immatics.com/

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer...